/NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES/
SAN DIEGO, CA and VANCOUVER, June 14, 2013 /CNW/ - Sophiris Bio Inc. (TSX: SHS) (the "Company" or "Sophiris"), in accordance with Toronto Stock Exchange requirements, announced the voting results for the election of its Board of Directors at the Annual Meeting of Shareholders held on June 12, 2013 in Vancouver, British Columbia. The director nominees, as listed in the Management Proxy Circular dated May 3, 2013, were elected as directors of the Company at the meeting. The proxy votes submitted for each director were as follows:
|Dr. Lars Ekman||85,131,509||99.99%||8,833||0.01%|
|Dr. John (Jack) Geltosky||85,131,509||99.99%||8,833||0.01%|
|William R. Rohn||85,131,509||99.99%||8,833||0.01%|
|Randall E. Woods||85,131,509||99.99%||8,833||0.01%|
The results of the other matters considered at the meeting are reported in the Report of Voting Results as filed on SEDAR on June 14, 2013.
The Company's statutory filings are available at www.sedar.com.
About Sophiris Bio:
Sophiris Bio Inc. is a urology company developing a clinical-stage, targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate), a market with significant demand. Sophiris' lead candidate for BPH, PRX302, is designed to be as efficacious as pharmaceuticals, less invasive than surgical interventions, and without the sexual side effects seen with existing treatments. For more information, please visit www.sophirisbio.com.
SOURCE: Sophiris Bio, Inc.
For further information:
The Trout Group
TMX Equicom Group
Jason I. Spark
Canale Communications, Inc.